The data was presented by Dr Tanios Bekaii-Saabfrom the Mayo Clinic at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
The highlight and key finding of the KEY-Vaxx presentation demonstrated that KEY-Vaxx, when combined with B-Vaxx, is more effective in reducing tumor growth in a validated mouse model of colon carcinoma versus either the PD-1 KEY-Vaxx vaccine alone.
The vaccine combination was found to be safe and did not appear to exhibit toxicity or autoimmunity.
Imugene is working to evaluate KEY-Vaxx and its potential efficacy in a range of cancers.
ASX NEWS: KEY-Vaxx PD-1/B-Vaxx HER-2 cancer vaccine combo inhibits tumor growth in mouse model of colon carcinoma & combo safe with no evidence of autoimmunity & KEY-Vaxx PD-1 cancer vaccine to be trialled in a range of cancers, lung cancer first https://t.co/UDejcS62wj #BioTech pic.twitter.com/nQDXO0vgRA— Imugene | Cancer Immunotherapies (@TeamImugene) April 1, 2019
New data from phase Ib study of HER-Vaxx
New data was also presented at the same event related to the phase Ib study of the HER-Vaxx cancer vaccine, in which 11 out of 14 evaluable patients showed clinically meaningful responses.
The phase 1b HER-Vaxx study reported no safety or toxicity issues and all evaluable patients showed increased antibody responses.
One patient saw a complete response, five had a partial response and four recorded a stabilisation of their disease.
Due to the success of the phase Ib trial, Imugene dosed its first patient in its phase II study in mid-March 2019.
Imugene’s managing director and CEO Leslie Chong said: “We are encouraged by the overall positive data from the phase Ib trial which clearly supports our B-cell platform cancer vaccine strategy for treating HER-2 positive gastric cancer.”
Recently, Imugene received minutes of its meeting with the (FDA) for its KEY-Vaxx cancer immunotherapy on 8 February 2019.
The meeting was aimed at seeking guidance on the studies required for phase I clinical development of KEY-Vaxx.